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Abstract
Background and Aims: To review the regenerative technologies used in bone regen-
eration: bone grafts, barrier membranes, bioactive factors and cell therapies.
Material and Methods: Four background review publications served to elaborate this 
consensus report.
Results and Conclusions: Biomaterials used as bone grafts must meet specific re-
quirements: biocompatibility, porosity, osteoconductivity, osteoinductivity, sur-
face properties, biodegradability, mechanical properties, angiogenicity, handling 
and manufacturing processes. Currently used biomaterials have demonstrated ad-
vantages and limitations based on the fulfilment of these requirements. Similarly, 
membranes for guided bone regeneration (GBR) must fulfil specific properties and 
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1  | INTRODUC TION
This consensus report aims to describe the regenerative technolo-
gies currently used in bone regenerative interventions in the cranio-
maxillofacial region. The relevant scientific evidence that served to 
elaborate this report came from four background publications, being 
three narrative reviews using a systematic search approach and one 
systematic review, respectively:
1 Bone grafts: which is the ideal biomaterial? Haugen HJ, 
Lyngstadaas SP, Rossi, F and Perale G
2 Barrier membranes: more than the barrier effect? Omar O, Elgali 
I, Dahlin C and Thomsen P
3 The use of bioactive factors to enhance bone regeneration. A nar-
rative review Donos N, Dereka X and Calciolari E
4 Cell therapy for orofacial bone regeneration: a systematic review 
and meta-analysis Shanbhag S, Suliman S, Pandis N, Stavropoulos 
A, Sanz M and Mustafa K
2  | BIOMATERIAL S USED A S 
BONE REPL ACEMENT GR AF TS IN 
REGENER ATIVE INTERVENTIONS IN THE 
C ARNIOMA XILLOFACIAL REGION
Biomaterials used as bone replacement grafts must meet specific 
requirements to achieve the goal of developing a new and healthy 
bone tissue formation:
1 Biocompatibility: The interaction between the material and the 
tissues should not adversely affect the surrounding tissues, the 
intended healing result or the safety of the patient. (Williams, 
2017). Ideally, biomaterials should be inherently bioactive in 
promoting the bone regeneration process (e.g., ion release and 
surface characteristics).
2 Porosity: An adequate pore size, morphology and inter-connectivity 
is needed to allow for diffusion throughout the whole scaffold of 
bone cells, nutrients and exchange of waste products. It is impor-
tant to distinguish between micro-porosity and macro-porosity 
(Hutmacher, 2000). Micro-porosity is defined as pores ≤10 μm to 
improve cell adhesion, to allow fluids and nutrients flow (permeabil-
ity) and thus to enhance the bioactivity. Macro-porosity is defined 
as pores ≥100 μm to allow for angiogenesis and to bone cell in-
growth, thus mimicking the porosity of trabecular bone, which has a 
mean value 250 μm, although it is highly variable. Inter-connectivity 
(the connection between pores) is also an important property to 
allow for permeability, vascularization and bone ingrowth.
3 Osteoconductivity/Osteoinductivity: All biomaterials used for bone re-
generation should allow for bone growth directly in contact with the 
biomaterial surface from the surrounding bone (osteoconduction), but 
ideally it should also be able to promote osteoinduction (Albrektsson 
potential biological mechanisms to improve their clinical applicability. Pre- clinical 
and clinical studies have evaluated the added effect of bone morphogenetic proteins 
(mainly BMP- 2) and autologous platelet concentrates (APCs) when used as bioactive 
agents to enhance bone regeneration. Three main approaches using cell therapies to 
enhance bone regeneration have been evaluated: (a) “minimally manipulated” whole 
tissue fractions; (b) ex vivo expanded “uncommitted” stem/progenitor cells; and (c) ex 
vivo expanded “committed” bone- /periosteum- derived cells. Based on the evidence 
from clinical trials, transplantation of cells, most commonly whole bone marrow as-
pirates (BMA) or bone marrow aspirate concentrations (BMAC), in combination with 
biomaterial scaffolds has demonstrated an additional effect in sinus augmentation 
and horizontal ridge augmentation, and comparable bone regeneration to autogenous 
bone in alveolar cleft repair.
K E Y W O R D S
barrier membrane, bio-absorbable, bioactive agent, biomaterials, bone regeneration, bone 
replacement graft, cell therapies, guided bone regeneration, osteoconductive, osteoinductive
Clinical Relevance
Bone regenerative interventions in the jaw bones and used 
widely, mainly in conjunction with dental implant therapy. 
The outcome of these interventions depends largely on 
the appropriate selection of the regenerative technology 
based, which should be based on a careful diagnostic as-
sessment of the defect site as well as a sound selection of 
the biomaterials, cells or differentiating factors to be used. 
In this consensus report, the evidence behind the efficacy 
of these technologies in the different clinical indications is 
presented.
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& Johansson, 2001). An osteoinductive biomaterial should first be 
capable of recruiting mesenchymal-type osteoprogenitor cells. 
Secondly, it should be capable of transforming an undifferentiated 
mesenchymal cell into a mature, bone-forming osteoblast. Lastly, it 
should be capable of inducing ingrowth of ectopic bone formation 
when implanted into extra-skeletal locations. This capacity may be 
related to its micro-porosity and surface properties.
4 Surface properties: Surface topography at the nano and micro level 
as well as surface physico-chemistry are important characteristics 
for protein adsorption, extracellular matrix deposition, cell adhe-
sion, differentiation, migration and finally bone formation.
5 Biodegradability: The capacity of the biomaterial to bio-absorb 
during the tissue healing and remodelling process. The ideal bone 
graft substitute is expected to be fully replaced by bone, prefer-
ably at a predictable absorption rate, without losing tissue vol-
ume and without interfering with the healing and regeneration 
process. In case of biomaterials with a slow bio-absorbability rate, 
these should assure a process of new bone formation with suf-
ficient volume in contact with the biomaterial.
6 Mechanical properties: Compressive strength and elasticity should 
be high enough to absorb the load from the surrounding hard and 
soft tissues in non-contained defects. Ideally, the compressive 
strength and elasticity of the biomaterial should be at least those 
of the natural bone at the site of regeneration. These mechanical 
properties are also influenced by pore morphology and size.
7 Angiogenicity: The inherent biomaterial properties (e.g., porosity 
and surface) should promote angiogenesis and the appropriate 
vascularization of the graft volume.
8 Handling: The biomaterial should be cohesive and dimensionally 
stable, and easy for chairside use to adapt to the defect. When 
used in non-contained defects, it should allow for three-dimen-
sional build-up. Biomaterials for craniomaxillofacial bone regen-
eration are usually available in the form of granules or blocks. 
Depending on the clinical needs, it is desirable to have a wide 
variability of sizes and forms, ranging from 0.1 to 2.0 mm in the 
particulate form (Haugen, Lyngstadaas, Rossi, & Perale, 2019). For 
certain indications an injectable mode of application would be de-
sired to fill the defect volume through its plasticity.
9 Manufacturing processes: The biomaterial should be provided with 
certification or documentation of the appropriate manufacturing 
and sterilization processes and assure long shelf time and reduced 
production costs.
2.1 | What are the advantages and limitations of the 
currently used bone grafts for craniomaxillofacial 
bone regeneration?
2.1.1 | Autologous
Even though autologous bone is not a biomaterial per se, it is con-
sidered the gold standard graft material for bone regeneration and 
it has the following advantages: it contains the patient's own cells, 
growth factors and biomolecules needed for osteogenesis, it has the 
highest degree of biological safety, biocompatibility, matched me-
chanical properties and scaffolding effect.
In regard to limitations, autologous grafts may need a second 
surgical site for its harvesting, which increases patient's morbidity, 
pain or discomfort and other complications related to increased sur-
gical time and invasiveness. It has been reported that the resorption 
of these bone replacement grafts is higher, and their rate of resorp-
tion is not predictable. Depending on the source of the graft (cortical 
vs. cancellous bone) the vascularization may be slowed, mainly in 
highly cortical bone grafts. It has also limitations in terms of volume 
availability, mainly when harvesting from intra- oral sources and the 
resulting grafts, mainly in a block form may be difficult to adapt to 
the anatomy of the defect.
The application of particulate dentin has been recently sug-
gested as another autologous source for minor ridge augmentation 
or socket site preservation. However, there is no clinical documenta-
tion to substantiate its clinical use.
2.1.2 | Allogenic
There are different ways of processing allogenic bone replacement 
grafts (freeze dried and fresh frozen), which may change their bio-
logical properties. These allografts can be produced as particulate 
or blocks. In principle, the general advantage of this biomaterial is 
that it provides similar mechanical properties as the autologous bone 
and it may contain the collagenous matrix and proteins of natural 
bone, although it lacks viable cells. Similarly, handling properties are 
comparable to autologous bone, although the reduced surgical time 
needed for their implantation, in addition to their increased avail-
ability are clear advantages when compared with autologous bone.
Its biological safety due to possible disease transmission and 
potential unwanted immune reactions are clear disadvantages. 
Furthermore, the sources of donor material are heterogeneous, 
what may influence their biological activity and similarly, resorption 
rate are highly variable. Other drawbacks could be possible impair-
ment to achieve vascularization of the grafted site. In the future its 
availability for clinical use may be reduced in the light of the regula-
tory changes in Europe.
2.1.3 | Xenogeneic
Deproteinized bovine bone mineral (DBBM) is the biomaterial with 
the most documentation in the scientific literature for bone grafting 
in the craniomaxillofacial area. Its main advantages are that since 
it is derived from both natural cancellous and cortical bone its ar-
chitecture and geometric structure resemble bone, although highly 
depending on the tissue source and manufacturing process. Its slow 
bio- absorbability may be a clinical advantage for preserving the aug-
mented bone volume.
In regard to limitations, it lacks biological components thus limit-
ing its biological activity. Similar to allogenic materials, its use implies 
a potential biological risk of disease transmission (e.g., prions and 
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retroviruses) and/or immunogenic host- tissue response, although 
these risks can be diminished through the manufacturing process 
(deproteinization). In spite of this inherent risk, however, transmis-
sion of bovine spongiform encephalitis (BSE) has not yet been re-
ported associated with the implantation of this biomaterial.
Mechanical properties (brittleness) may vary depending on the 
source and manufacturing process. Since these biomaterials are 
mainly available for use in particulate form, they may have limita-
tions in large defect regeneration interventions.
2.1.4 | Synthetic bio ceramics
Calcium sulphate, calcium phosphate (CaP), bioactive glass and com-
binations are the most commonly used bio ceramics available at pre-
sent. Their main advantage is the controlled manufacturing process 
which may assure biocompatibility, biodegradability and similarity in 
structure and inorganic composition to natural bone minerals. The 
most investigated CaP bone graft substitutes are hydroxyapatite 
(HA), β- tricalcium phosphate (β- TCP) and their combination, also 
called biphasic calcium phosphate (BCF). Bio ceramics have shown 
osteoinductive properties through the stimulation of inorganic ma-
trix deposition, osteoblast differentiation, osteoblast growth and 
bone promotion. By modulating their chemical composition and 
sintering temperature their bioactivity and degradation time can be 
controlled to a certain extent.
Their main disadvantage is associated with their limited me-
chanical properties (load bearing resistance) and unpredictable bio- 
absorption rates. They are mainly delivered as particulates, which 
may limit their use in large bone defects.
Glass- based ceramics share the same problems of lower mechan-
ical strength despite excellent material- bone interactions. Similarly, 
their degradation times can be unpredictable.
To improve their mechanical therapies (brittleness), bio ceram-
ics have been mixed with polymers developing composite materials 
(Laurencin, Ashe, Henry, Kan, & Lo, 2014).
2.1.5 | Synthetic polymers
The most studied synthetic polymers used as biomaterials for bone 
tissue regeneration are aliphatic polyesters like poly (lactic- acid) 
(PLA), poly (ε- caprolactone) (PCL), and poly (glycolic acid) (PGA) and 
their copolymers and derivatives. They share the advantage that 
their manufacture is controllable and tunable in terms of adjust-
ing their physiochemical structure, porosity, and hence their bio-
degradability and shape, size and biomechanical properties can be 
customized.
Their most important limitation is that they have not demon-
strated osteoconductivity and hence, their use as bone replacement 
grafts requires their combination with bio ceramics as composite 
materials or they can be functionalized, for example with different 
coatings. Their process of bio- absorbability usually leads to the re-
lease of acid compounds that may interfere with wound healing, 
although this limitation can be controlled by the manufacturing 
process as composite materials can be combined with bio ceramics. 
Furthermore, the bio- absorbability of synthetic polymers is highly 
variable, which may impair their mechanical strength in vivo.
2.1.6 | Composite biomaterials
Composite biomaterials are biomaterials generated by combining bio 
ceramics with polymers or xenogeneic biomaterials together with 
bio ceramics or polymers. Their properties will vary depending on 
their composition and manufacturing processes.
2.1.7 | Other synthetic biomaterials
Granules made of titanium particles were marketed for use in bone 
regeneration, although their use is no longer available in the market.
2.2 | Recommendations for future research
The future of craniomaxillofacial bone regeneration will probably 
entail the manufacturing of personalized biomaterials from 3- D digi-
tal data obtained from patients. Additive manufacturing (e.g., 3- D 
printing) of different biomaterials (e.g., bio ceramics) will allow rapid 
production of these customized scaffolds that will perfectly fit the 
bone defect anatomy. The addition of synthetic polymers in the de-
sign of composite biomaterials may mechanically reinforce these 3D 
constructed biomaterials. Similarly, the addition of cells (bio- printing) 
may add biological activity to the 3- D printed constructs.
Future biomaterials should have optimized surface characteris-
tics, pore size and interconnection. These characteristics will be ad-
justed to control of their bio- absorbability, promote osteoinduction 
and ensure ideal mechanical properties.
Biomimetic biomaterials should be developed at ambient tem-
peratures by hydrolysis and precipitation of calcium deficient ap-
atite, what will result in similar composition and crystallinity as 
natural bone. These biomaterials should be completely replaced by 
new bone through controlled processes of bio- absorbability and 
osteoinduction.
There is a need of standardized and validated pre- clinical models, 
with the use of small animal models for screening and large- animal 
models for comparing new biomaterials using established standards. 
In concordance with the ARRIVE guidelines to reduce animal re-
search, there is a need for standardized pre- clinical models, such as 
in silico modelling and ex vivo tissue engineering testing to reduce 
animal research.
3  | MEMBR ANES FOR GUIDED 
BONE REGENER ATION USED IN 
REGENER ATIVE INTERVENTIONS IN THE 
C ARNIOMA XILLOFACIAL REGION
This report addresses the scientific evidence on the effects of mem-
branes used for guided bone regeneration (GBR), focusing on their 
86  |     SANZ et Al.
properties and potential biological mechanisms, regardless of the 
clinical applicability (Omar, Elgali, Dahlin, & Thomsen, 2019).
Ideally, a new developed membrane should pass the cascades 
of evaluations from in vitro to clinical testing until being approved 
as medical devices according to current ISO standards and specifi-
cations. In addition, the new European Medical Device Regulation 
(EU- MDR) for implantable medical devices requires confirmation of 
the product claims through prospective clinical studies.
Beside their inherent barrier effect, membranes for guided bone 
regeneration should have certain properties:
1 Biocompatibility: The biomaterial shall perform with an appropri-
ate tissue response. Hence, the interaction between the material 
and the tissues should not adversely affect the surrounding 
tissues, the intended healing result or the safety of the patient. 
(Williams, 2017).
2 Biological activity: There is increasing evidence that membranes 
not only function due to their occlusive properties, but they ac-
tively promote bone regeneration within the osseous defect below 
the membrane. Specifically, this biological activity may include re-
cruitment of cells, angiogenesis, bone formation and bone remod-
elling leading to bone fill of the defect with mature bone. There 
is experimental evidence that collagen membranes allow inward 
migration of cells that express and secrete osteogenic and angio-
genic factors. It is not yet established whether similar biological 
processes are shared by membranes of different composition.
3 Porosity/occlusive properties: A defined porosity or a certain degree 
of barrier effect of the membrane are not prerequisites for their 
use in guided bone regeneration, although these properties may 
affect the regenerative outcomes. There is a wide variability in the 
pore size and degree of permeability in the commercially available 
membranes for GBR, ranging from micro-porosity (5–20 μm), which 
may limit the passage of cells, but allows the passage of chemicals, 
biomolecules, viruses; moderate porosity (non-resorbable materi-
als ≤100 μm) that also allows the passage of bacteria, cells and tis-
sue integration/migration (tissue integration occurs ≥30–40 μm); 
macro-porosity (non-resorbable materials >100 μm) which allows 
unrestricted passage of chemicals, biomolecules, viruses, bacteria, 
cells and allows tissue integration and migration. The pore size can 
increase during the process of membrane degradation within the 
tissue, which may in turn influence its bioactivity, passage of nutri-
ent and cells and the ingrowth of nutrients and soft and hard tissue 
cells. The optimal membrane porosity has not been defined yet.
4 Mechanical properties: The ideal GBR membrane should be suf-
ficiently rigid for an adequate space-making capacity and able to 
withstand the pressure of the overlying soft tissues during func-
tion in order to prevent its collapse. At the same time. It should 
possess certain degree of plasticity and elasticity to be easily con-
toured and adapted to the anatomy of the defect. In situations 
where the membrane does not possess the required mechanical 
properties, it should be combined with a bone replacement bio-
material/graft that serves as a scaffold, to attain the desire vol-
ume of regenerated bone.
5 Integration with the tissues: The integration of the membrane with 
the adjacent connective tissues is essential for optimal primary 
wound closure and healing. In fact, lack of integration and mem-
brane exposure is associated with inferior regenerative outcomes. 
There is evidence that mobility of the membrane and lack of hy-
drophilicity will impair connective tissue integration and bone 
formation. In case of non-resorbable membranes, the degree of 
tissue integration should be coupled with an easy and atraumatic 
removal. There is lack of information on the optimal degree of 
membrane tissue integration during healing.
6 Exposure tolerance: Membrane exposure and its subsequent bac-
terial contamination may hamper the regenerative outcomes 
irrespectively whether the membrane is biodegradable or non-
resorbable. In case of exposure, the exposed membrane should 
be kept in situ and continue to function during the regenerative 
process, although in case of overt infections, its removal should 
be considered. When combined with biomaterials, the incidence 
of infections might increase.
7 Biodegradability: Systematic reviews have shown comparable 
clinical outcomes between resorbable and non-resorbable mem-
branes. However, there is clear evidence that the membrane must 
retain its function for a certain amount of time to achieve a pre-
dictable regenerative outcome. In fact, the longer the membrane 
maintains its function the greater the maturity of the bone is, al-
though in spite of 30 years of GBR research, the ideal membrane 
bio-absorption time has not yet been established. Moreover, the 
inflammatory response elicited by the degradation of the mem-
brane should not adversely affect the regenerative outcome.
3.1 | What are advantages and limitations of 
currently available membranes used in GBR?
3.1.1 | PTFE and modifications
Due to its synthetic nature, PTFE membranes have the advantage 
of not eliciting any immunological reaction and being resistant to 
breakdown by the host tissues. Compared with biodegradable mem-
branes, they have superior space- making capability, mainly when 
these membranes have titanium reinforcement, which makes them 
the ideal membranes for vertical bone regeneration. Their main 
limitation is the increased frequency of membrane exposure with 
a subsequent risk for bacterial contamination and infection, in fact 
superior regenerative outcomes with these membranes are associ-
ated with a closed uneventful healing. Other limitation is the diffi-
culty in their removal due to their soft tissue integration. Moreover, 
the cost of PTFE membranes is higher compared to biodegradable 
membranes.
3.1.2 | Synthetic polymers
The main advantages of polymeric membranes are their manage-
ability, process ability, tuned biodegradation and drug- encapsulating 
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ability. However, their degradation might elicit a strong inflamma-
tory response, leading to resorption of the regenerated bone. The 
resorption rate of these types of membranes is largely dependent on 
the type of polymer used.
3.1.3 | Naturally derived membranes
Collagen (non- crosslinked)
Collagen- based membranes are the most commonly used natu-
rally derived membranes for GBR and their degradation does not 
exert any potential deleterious effect to the tissues. Their use has 
not been associated with relevant adverse effects since collagen is 
the principal component of connective tissues, playing important 
role in tissue structural support and in cell matrix communication. 
Their main limitation is their lack of rigidity, which limits their space- 
making capabilities and requires their combination with a scaffold, 
Yet, collagen membranes can be used alone for alveolar bone de-
fects which do not require extra fixation and stability such as bone 
dehiscence and fenestration defects. Moreover, since their degra-
dation is fast they may not meet the duration of time required for 
optimal tissue regeneration.
Chemically modified collagen
In order to slow down the bio- absorption process of collagen mem-
branes, a number of different methods of physical/chemical cross- 
linking have been developed, which may also enhance the membrane 
mechanical properties. Although chemical cross- linking has resulted 
in improvement of collagen stability, release of chemicals residues 
(e.g., amides or aldehydes) has been associated with severe inflam-
mation at the implantation site. Generally, the predictability of the 
collagen membrane not only depends on the origin of the collagen 
material but also its preparation and manufacturing process (e.g., de- 
cellularization, sterilization and method of cross- linking).
Chitosan, alginate
Their material properties include biocompatibility, biodegradability, 
low immunogenicity and a bacteriostatic effect. Experimental re-
sults indicate similar regenerative outcomes when compared with 
collagen membranes. Despite the experimental studies, their clinical 
use for GBR has not been documented.
Metals
Titanium is a commonly used material in dentistry. Amongst its 
properties are biocompatibility, high strength and rigidity for space 
maintenance, low density and weight, the ability to withstand high 
temperatures, and resistance to corrosion. The use of titanium for 
GBR was inspired from a successful outcome of using a titanium mesh 
for reconstruction of maxillofacial defects. Titanium mesh alone or 
with bone substitutes is a procedure for localized alveolar ridge 
augmentation prior to, or simultaneously with, implant placement. 
Occlusive titanium and micro- perforated titanium membranes have 
also been introduced and used for treatment of peri- implant bone 
defects and ridge augmentation. Limited experimental data exist on 
CoCr membrane for bone augmentation. Their limitations include dif-
ficulties in their removal due to connective tissue integration, mainly 
associated with the titanium mesh. Conversely, lack of tissue integra-
tion has been reported with the use of solid titanium materials.
3.2 | What is the role of the exogenous 
administration of biological cues to the membrane?
The use of growth factors and/or cell therapies have provided prom-
ising experimental results when used in combination with GBR, 
mainly in combination with resorbable membranes. The evidence of 
efficacy in clinical trials is, however, lacking and these strategies may 
be hampered by financial and regulatory constraints as well as for 
the potential adverse risks associated with these therapies.
3.3 | Recommendations for future research
The bone promoting environments in the membrane and defect 
compartment during GBR can likely be optimized by several strate-
gies targeting both material aspects and host- tissue responses.
The membrane, the main component of GBR, can be improved 
depending on the functional requirements and the involved biolog-
ical mechanism. These modifications may include the following: (a) 
optimizing the physicochemical and mechanical properties, for ex-
ample, the porosity, structure, thickness, rigidity and plasticity; (b) 
incorporating biological factors and synthetic bioactive materials; 
and (c) incorporating antibacterial agents and antibiotics.
From scientific, developmental and clinical perspectives, new 
developments in tissue engineering and drug delivery may enhance 
the barrier concept associated with GBR and expand the clinical op-
portunities for bone regeneration in the future.
4  | BIOAC TIVE FAC TORS USED IN 
REGENER ATIVE INTERVENTIONS IN THE 
C ARNIOMA XILLOFACIAL REGION TO 
ENHANCE BONE REGENER ATION
Bioactive agents or factors are defined as natural mediators of tissue 
repair capable of eliciting a response from a living tissue, organism or 
cell. The majority of pre- clinical and clinical studies on bone regener-
ation have focused on bone morphogenetic proteins (mainly BMP- 2) 
and autologous platelet concentrates (APCs). Less evidence is avail-
able for other growth factors (mainly platelet- derived growth factor 
PDGF- BB, fibroblast growth factor FGF- 2 and vascular endothelial 
growth factor VEGF) and amelogenins (Donos, Dereka, & Calciolari, 
2019). The combination of different bioactive factors has also been 
proposed, with the aim to reduce the dosages of each factor (and 
associated side effects) and, at the same time, promote synergistic 
effects. While significant literature has documented the use of bio-
active factors (mainly amelogenins, FGF- 2, PDGF- BB and APCs) for 
the regeneration of periodontal intrabony defects, it is outside the 
remit of this consensus to comment on periodontal regeneration.
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4.1 | What are the advantages of the use of 
bioactive factors in bone regeneration?
The consensus was based on a critical review assessing the out-
comes of the use of bioactive substances in pre- clinical models and 
clinical applications. The pre- clinical bone regeneration models 
included ridge/socket preservation, alveolar ridge augmentation 
(horizontal and vertical), regeneration of bone defects at the mo-
ment of implant placement, sinus augmentation and regeneration 
of critical/sub- critical bone defects. The clinical evidence is based 
only on RCTs, CCT and Case Series (>5 cases) that included histo-
logical and/or radiographical assessment of bone regeneration for 
ridge preservation, ridge augmentation, regeneration of bone de-
fects at the moment of implant placement and sinus augmentation.
4.1.1 | Bone morphogenetic protein (rhBMP- 2)
Overall, pre- clinical studies suggest that rhBMP- 2 (at different 
dosages) significantly promotes, either directly or indirectly, bone 
regeneration in critical and sub- critical size bone defects and de 
novo bone formation regardless of the carrier adopted. rhBMP- 2 
enhances ridge augmentation in chronic and combined defects and 
promotes ridge preservation. Conflicting results have been reported 
regarding the benefits in peri- implant circumferential defects and 
sinus augmentation. In challenging ridge augmentation or peri- 
implant defects the combination with a space- providing material is 
recommended.
As a carrier, the absorbable collagen sponge (ACS) can be suc-
cessfully used, with or without space- providing materials. For clinical 
application, an ACS carrier impregnated with rhBMP- 2 was approved 
by the Food and Drug Administration for ridge preservation and 
sinus augmentation. Therefore, most of the clinical studies have em-
ployed BMP- 2/ACS, although a combination of rhBMP- 2 with differ-
ent grafts has also been suggested. Clinical studies suggest 1.50 mg/
ml as the optimal dosage for ridge preservation and a range between 
1.05 and 4.2 mg/ml for ridge augmentation purposes, while in some 
studies on sinus augmentation high supra- physiological doses of up 
to 48 mg of BMP- 2 per subject have been reported.
Based on 3 RCTs, rhBMP- 2/ACS combined with osteoconductive 
grafts and/or a titanium mesh for ridge augmentation is comparable 
to autologous bone and titanium mesh or deproteinized bovine bone 
mineral based on radiographic/histological outcomes. In a recent 
RCT of 4 months duration, the use of autologous block grafts was 
superior in terms of amounts of mineralized tissue when compared 
to DBBM block grafts loaded with BMP- 2. Three RCTs have used 
BMP- 2 combined with ACS or other carriers for ridge preservation. 
The evidence of using rhBMP- 2 in regeneration of bone defects 
following implant placement is scarce. The results of the studies 
using rhBMP- 2 as a graft material in sinus floor augmentation are 
conflicting.
Amongst the available bioactive factors BMP- 2 is supported 
with the highest evidence, albeit heterogeneous. The existing 
RCTs suggest that there is a similar beneficial effect of rhBMP- 2/
ACS compared to commercially available bone grafting materials for 
socket preservation and ridge augmentation. Currently, this material 
has not been approved in Europe for clinical use in oro- maxillofacial 
applications.
4.1.2 | Other growth factors (PDGF- BB, FGF- 2, 
VEGF)
Direct administration of PDGF- BB, FGF- 2 and VEGF with differ-
ent carriers and indirect administration has been studied in pre- 
clinical studies with demonstration of enhanced bone regeneration 
when used with GBR. The available evidence for their use for ridge 
preservation is not robust enough to draw conclusions and make 
recommendations.
Studies in chronic alveolar defects have shown that rhPDGF- BB 
combined with block or particulate grafts can significantly promote 
ridge augmentation. It is unclear whether the addition of a barrier 
membrane has an impact on the final regeneration outcome. The 
pre- clinical evidence that rhFGF- 2 associated with different syn-
thetic biomaterials can promote ridge augmentation is still not ro-
bust. There is limited evidence from experimental studies suggesting 
that rhPDGF- BB alone or combined with IGF- 1 or bone grafts might 
enhance the regeneration of peri- implant defects. There is insuffi-
cient evidence on the use of growth factors other than BMP- 2 for 
sinus augmentation.
rhPDGF- BB and rhGDF- 5 are the growth factors, apart from 
rhBMPs, which have been evaluated in clinical studies for bone re-
generation when combined with different bone replacement grafts. 
The available studies have used 0.5 ml PDGF- BB at concentration 
of 0.3 mg/ml, and between 500 μg to 500 mg rhGDF- 5 per gram of 
β- TCP. There is limited evidence on the efficacy of rhPDGF- BB for 
ridge preservation and ridge augmentation. RCTs are needed to clar-
ify whether rhPDGF- B combined with different grafting materials 
can promote post- extraction ridge preservation and the horizontal 
and vertical regeneration of alveolar defects. No controlled studies 
have investigated the use of rhPDGF- BB for the treatment of peri- 
implant defects and there are only limited studies reporting on the 
use of rhPDGF- BB or rhGDF- 5 for sinus augmentation. Therefore, 
no robust conclusions could be drawn.
4.1.3 | Enamel matrix derivatives (EMD)
Although various fractions of EMD have shown osteoinductive 
properties, only few pre- clinical studies have investigated the use of 
amelogenins (EMD) for bone regeneration. EMD has limited effect in 
enhancing bone formation and does not offer significant advantages 
over the use of a membrane or a bone graft or the combination of 
both.
The available clinical evidence does not support the use of EMD 
in sinus augmentation, ridge augmentation, ridge preservation or 
bone defects following implant placement.
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4.1.4 | Autologous platelet concentrates (APCs)
Autologous platelet concentrates are intended to enhance bone 
regeneration by triggering the natural healing process with a sup-
plement of highly concentrated bioactive factors. One of the main 
challenges in reviewing the scientific evidence is the heterogene-
ity of the APC preparation protocols and accuracy in the use of the 
terminology.
Some pre- clinical studies have shown that Platelet Rich Plasma 
(PRP) or Platelet Rich Fibrin (PRF) compared to spontaneous heal-
ing, fibrin glue derived from platelet poor plasma, collagen sponge 
or hydrogel improve the amount and quality of regeneration of ex-
perimentally induced bone defects. However, there is no robust ev-
idence supporting the addition of these APCs to bone grafts or for 
de novo bone formation.
The evidence on the potential of plasma rich in growth factors 
(PRGF) to promote bone regeneration in experimentally induced 
bone defects is limited. Regarding the use of all APCs, there is in-
sufficient evidence for ridge/socket preservation, regeneration of 
bone defects after implant placement and sinus augmentation. The 
limited pre- clinical studies on the use of PRP for ridge augmentation 
suggest that, while autologous bone remains the gold standard, the 
combination of PRP, cells and different bone substitutes could be a 
promising alternative.
Clinical research has shown that the combined therapy of APCs 
with bone grafts and/or cells offer promising results for ridge aug-
mentation procedures. More RCTs are needed to clarify which of the 
APCs is superior. For ridge preservation procedures, APCs may ac-
celerate clinical healing, soft tissue epithelialization and reduce post-
operative pain, but there is insufficient and contrasting evidence of 
a significant effect on hard tissue regeneration. The clinical effect 
of APCs on defects after implant placement has been studied in a 
limited number of investigations but the available evidence does not 
allow for robust conclusions. Conflicting outcomes in terms of bone 
formation and implant stability emerged from the available studies 
on the use of APCs for sinus augmentation, with no clear benefits of 
one APC over the other.
4.2 | What are the limitations of the use of growth 
factors for bone regeneration?
When evaluating the application of growth factors for bone regen-
eration, there is lack of a clear understanding of their mechanism of 
action, the ideal dosage, frequency and mode of administration and 
the delivery system. Furthermore, there is a clear need for develop-
ing standardized protocols for controlling their release and clearance 
at the application site. In general, despite some encouraging results, 
the available evidence does not support the use of bioactive factors 
as a routine alternative to the currently used bone regenerative in-
terventions in the craniomaxillofacial area.
High dosages of rhBMP- 2 have been associated with side ef-
fects, including long- lasting oedema formation, as well as mucosal 
erythema, osteoclast- mediated bone resorption and inappropriate 
adipogenesis. Combinations of rhBMP- 2 with other growth factors 
(pre- clinical studies) have been suggested to reduce these dosage- 
related complications of rhBMP- 2.
Moreover, a concern that could be raised on the use of rhBMP- 2 
is the development of immunological factors, such as anti- rhBMP- 2 
and anti- bovine collagen type I (6% and 20% incidence, respectively, 
as per FDA report on rhBMP- 2/ACS).
4.3 | Recommendations for future research
Well- designed and adequately powered RCTs showing clinical and 
histological outcomes of bioactive agents are required to clarify their 
potential and actual need in regenerative dentistry.
In the future, studies need to be designed to overcome the het-
erogeneity currently present in the literature concerning biological 
agent's dosage, formulation, concomitant biomaterials used, types 
of defects, methods of investigation and follow- up periods.
Research efforts should be also directed towards the devel-
opment of delivery systems enabling controlled spatial- temporal 
delivery of single or combination of bioactive factors. The ultimate 
aim should be mimicking the synergistic wound healing activity 
of the combinational release profiles of growth factors and ex-
tracellular matrix components that occurs in physiological wound 
healing.
5  | CELL THER APIES USED IN 
REGENER ATIVE INTERVENTIONS IN THE 
CR ANIOMA XILLOFACIAL REGION TO 
ENHANCE BONE REGENER ATION
This consensus report is based on the review of the evidence from 
pre- clinical and clinical studies on the use of cell therapies for cranio-
maxillofacial bone regeneration (Shanbhag et al., 2019). Three main 
approaches using cell therapies have been evaluated: (a) “minimally 
manipulated” whole tissue fractions; (b) ex vivo expanded “uncom-
mitted” stem/progenitor cells; and (c) ex vivo expanded “commit-
ted” bone- /periosteum- derived cells. Minimally manipulated whole 
tissue fractions, preserve the physiological microenvironment or 
“niche” of multiple cell types in their natural ratios; these mainly in-
clude bone marrow aspirates – either whole (BMA) or concentrated 
(BMAC), adipose stromal vascular fractions (A- SVF), and tissue “mi-
crograft.” The major limitation of this approach is that mesenchymal 
stem (and progenitor) cells (MSCs) represent a very limited fraction 
of the implanted cells.
Ex vivo expansion strategies exponentially increase the number 
of cells of a specific phenotype, that is, uncommitted or committed, 
available for transplantation. The most commonly used source of 
uncommitted MSCs is the bone marrow (BMSCs), but more recently 
less invasive sources such as adipose tissue (ASCs) and dental tis-
sues, have been tested. Sources of committed cells are the perios-
teum and cancellous bone/marrow of the alveolar bone itself. The 
major limitation of ex vivo expansion strategies is the need for 
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highly sophisticated laboratories according to Good Manufacturing 
Practices (GMP), thereby significantly increasing the cost of this 
therapy.
5.1 | What is the effect of cell therapies 
(either whole tissues or ex vivo expanded 
cells) added to biomaterials or autologous 
bone, or combinations thereof, when compared 
with biomaterials or autologous bone 
alone, or combinations thereof, for the different 
clinical indications in the craniomaxillofacial area?
Clinical studies have evaluated cell therapies, mainly BMA and 
BMAC, in combination with biomaterials or autologous bone, or 
combinations thereof versus relevant controls in various indications 
(e.g., sinus augmentation, horizontal ridge augmentation and alveo-
lar cleft defects) and at various observation times. The clinical evi-
dence is mostly based on randomized (sinus and ridge augmentation) 
and non- randomized controlled trials (alveolar cleft repair).
Specifically:
1 In sinus augmentation, significantly more bone regeneration was 
observed after cell therapy in 1 meta-analysis of histomorpho-
metric results (six studies, vs. scaffolds, 6 months) and in 1 me-
ta-analysis of micro-computed tomography (μ-CT) results (three 
studies, vs. scaffolds, 4–7 months), while in 1 meta-analysis of 
histomorphometric results no benefit was observed (12 studies, 
vs. scaffolds, 3–4 months). Based on a meta-regression analy-
sis of histomorphometric data from 15 studies, there were no 
differences between the various cell therapy strategies, that is 
whole tissues versus expanded uncommitted cells versus expanded 
committed cells, in terms of the amount of bone regeneration.
2 In horizontal ridge augmentation, significantly more bone re-
generation was observed after cell therapy in 1 meta-analysis of 
histomorphometric results (three studies, vs. scaffolds; one study, 
vs. scaffolds + autogenous bone, 4–6 months).
3 In alveolar cleft defects, one meta-analysis failed to show a ben-
efit of cell therapy over autogenous bone, as evaluated with CT 
(three studies, 6 months).
4 Limited clinical evidence suggests that the “conditioned me-
dium” or “secretome” from MSCs may promote bone regenera-
tion in sinus augmentation (one study [four patients], vs. scaffold, 
6 months).
The above observations are in general supported by the results of 
meta- analyses of pre- clinical in vivo studies in large animals, which 
have mainly evaluated ex vivo expanded “uncommitted” cells, mainly 
BMSCs, in combination with biomaterials versus relevant controls in 
various models (e.g., sinus augmentation, critical size defects and al-
veolar cleft defects) and platforms (e.g., dogs, pigs and sheep/goats) 
at various observation times.
Based on the data from the clinical studies, the following conclu-
sions may be derived:
1 Transplantation of cells, most commonly whole BMA or BMAC, 
in combination with biomaterial scaffolds results in superior 
bone regeneration compared to implantation of scaffolds alone 
in sinus augmentation and horizontal ridge augmentation, and 
comparable bone regeneration to autogenous bone in alveolar 
cleft repair.
2 Based on studies of sinus augmentation, no superiority of ex 
vivo expanded cells, either uncommitted or committed, over 
whole tissue fractions (BMA/C or A-SVF) was observed. 
However, the appropriateness of sinus augmentation as a 
model to test cell therapies and detect clinically relevant ben-
efits may be questioned, owing to the “self-healing” capacity in 
this site (Duan et al., 2017).
3 The analysed studies, both clinical and pre-clinical, showed a 
wide range of effect sizes and prediction intervals, suggesting 
a high degree of heterogeneity, and emphasizing the need for 
well-designed future studies to ascertain the true effect of cell 
therapies.
5.2 | Is osteogenic pre- differentiation in ex vivo 
expansion strategies beneficial?
Based on limited evidence from pre- clinical in vivo and uncontrolled 
clinical studies, use of pre- differentiated BMSCs has not demon-
strated a significant added effect in terms of enhancing bone re-
generation compared with using undifferentiated BMSCs, while 
osteogenic pre- differentiation of ASCs or the addition of osteoin-
ductive factors, for example, BMP- 2, seemed to enhance bone re-
generation. However, no included studies in the review (pre- clinical 
or clinical) directly compared pre- differentiated cells versus undif-
ferentiated cells, either BMSCs or ASCs.
Based on this limited evidence:
1 In BMSCs, osteogenic pre-differentiation may not show any 
additional beneficial effect.
2 In ASCs, additional osteogenic stimulation, via pre-differentiation 
or addition of osteoinductive factors, for example, BMP-2, may be 
beneficial.
5.3 | Recommendations for future research
The relatively large effect sizes in favour of cell therapy observed in 
pre- clinical in vivo studies are diminished in clinical trials, suggesting 
a gap in translation and the need for better pre- clinical models.
Vascularization remains a key challenge in cell therapy, espe-
cially in large defects, since an inadequate vascularization in the 
internal parts of the cell- scaffold construct can impair cell survival 
and thereby compromise clinical outcomes. Promising pre- clinical 
research has been conducted in the area of “pre- vascularized” 
bone constructs but remains to be translated clinically.
The potential of using allogeneic cells as an “off- the- shelf” ther-
apy has been tested with favourable results in a limited number of 
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pre- clinical studies. However, the possibilities of immune reactions 
associated with using allogeneic human cells are still unclear and 
require further investigation (Kiernan, Wolvius, Brama, & Farrell, 
2018).
The potential use of “cell- free” strategies, which exploit the para-
crine or trophic effects of MSC- secretomes to promote regenera-
tion, should be explored. Similarly, alternative mechanisms of MSC 
activity, for example, via “empowerment” of host cells and modula-
tion of immune cells in the context of bone regeneration should be 
investigated (Wang, Chen, Cao, & Shi, 2014).
There is a need to evaluate the cost- effectiveness of cell therapy 
in comparison to current standards of care. Moreover, there is a need 
of well- designed studies to evaluate the efficacy/cost- effectiveness 
of different cell therapy strategies, that is, whole tissues versus ex-
panded uncommitted cells versus expanded committed cells.
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